Vertex Pharmaceuticals price target raised to $450 from $433 at Scotiabank
Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform ...
Vertex Pharma upgraded at Canaccord Genuity after Q4 results
Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.
Vertex Pharmaceuticals upgraded to Hold from Sell at Canaccord yesterday
As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...
Healthcare Dive1d
A new, non-opioid pain drug is here. Getting it to patients could be agony.
After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...
Piper Sandler maintains Vertex stock Overweight with $533 target
Piper Sandler expressed continued confidence in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), maintaining an Overweight ...
Vertex stock price target lifted to $444 by Bernstein
Bernstein SocGen Group adjusted its price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), increasing it slightly from $441.00 to $444.00 while maintaining a Market Perform rating. With a ...
Vertex Forecasts Upbeat 2025 Revenue on Cystic Fibrosis Treatments Demand
Vertex sees 2025 revenue of $11.75 billion to $12.0 billion, the midpoint of which is above analysts' average expectation of ...
India's Adani ties up with US based Mayo Clinic for affordable health campuses
Indian billionaire Gautam Adani on Monday said his family will invest over 60 billion rupees ($686.18 million) to launch two ...
BioSpace5d
FDA Approval of Vertex’s Non-Opioid Journavx Signals New Era in Pain Treatment
If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...